This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics On-Demand
Antibody Engineering & Therapeutics Anytime, Anywhere
Book Now and Start Streaming Today
BOOK NOW
Menu
BOOK NOW
Antibody Engineeringkeyboard_arrow_right

Antibody Engineering

search
Antibody Engineering
search
Antibody Engineering 00:00 - 00:30
Design of Therapeutic Antibody with Engineered Binding Specificity
  • Tomoyuki Igawa, PhD - Head of Research, Chugai Pharmaceutical Co., Ltd.
Antibody Engineering 00:30 - 01:00
Next-Generation Antibody Engineering and Design
  • Ryo Matsunaga, PhD - Assistant Professor, Bioengineering; Tsumoto Laboratory, The University of Tokyo
Antibody Engineering 01:00 - 01:30
Machine Learning-guided Protein Engineering of Immune Receptors
  • Sai Reddy, PhD - Associate Professor of Systems and Synthetic Immunology, ETH Zurich
Antibody Engineering 01:30 - 02:00
Integration of AI and Wet Lab for the Design of Novel Antibodies
  • Satoshi Tamaki, PhD - CEO and CSO, MOLCURE Inc.
Antibody Engineering 02:00 - 02:30
Development of the DXd ADC Technology Platform and the Latest Clinical Results
  • Yasuyuki Kaneta, PhD - Senior Director, Discovery Research Laboratories I, Daiichi Sankyo
Antibody Engineering 02:30 - 03:00
Development Overview of Bispecific DuoBody®-PD-L1×4-1BB (Acasunlimab): Next Generation Cancer Immunotherapy
  • Ben Hatano, MD, PhD - Head of Clinical Science, Genmab
Antibody Engineering 03:00 - 03:30
Novel Bispecific Antibody Format with Reliable Productivity and Developability and Its Product Application
  • Makoto Nakayama - Director, Antibody & Biologics Group, Kyowa Kirin
Antibody Engineering 03:30 - 04:00
PD-1 Pathway Blockade: A Common Denominator for Cancer Therapy
  • Suzanne Topalian, MD - Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine
Antibody Engineering 04:00 - 04:30
Antibody-guided Vaccine Design
  • Bryan Briney, PhD - Associate Professor, Department of Immunology and Microbiology, The Scripps Research Institute
Antibody Engineering 04:30 - 05:00
Design of New Protein Functions Using Deep Learning
  • David Baker, PhD - Professor of Biochemistry and Director, Institute for Protein Design, University of Washington
Antibody Engineering 05:00 - 05:30
DuoBody-EpCAMx4-1BB Facilitates Conditional T-cell Co-stimulation and Augments Antitumor Activity in Preclinical Studies
  • Andrea Imle, PhD - Associate Director, BioNtech SE
Antibody Engineering 05:30 - 06:00
BiCE™ – An Antibody Platform to Potentiate Complement Activation for the Treatment of Cancer and Autoimmune Diseases
  • Mikael Winkler, Ph.D. - CTO & Co-founder, Commit Biologics
Antibody Engineering 06:00 - 06:30
Machine Learning-guided Design of Next-generation Logic Gated and Avidity-driven T Cell Engagers for Patients with Solid Malignancies
  • Ryan Henrici, M.D., Ph.D. - Senior Director, Translational Research, BigHat Biosciences
Antibody Engineering 06:30 - 07:00
Bispecific Antibodies for Oncology and Autoimmune Diseases
  • John Desjarlais, PhD - Chief Scientific Officer, Xencor, Inc.
Antibody Engineering 07:00 - 07:30
Harnessing Alector Brain Carrier (ABC) to Deliver Novel Neuroimmunology Therapies to the CNS
  • Eric Brown, Ph.D. - Associate Director, Protein Engineering, Alector
Antibody Engineering 07:30 - 08:00
Overcoming the Membrane Mountain: Roadmap to Biotherapeutic Discovery Against Complex Membrane Targets Using Next-Gen Antibody and Antibody Fragment Libraries
  • Jeff Barker, Ph.D. - Principal Research Scientist I, AbbVie Bioresearch Center
Antibody Engineering 08:00 - 08:30
Antibody Engineering to Maximize the Clearance of Abundant Targets
  • Sofie Voet, Ph.D., Argenx
Antibody Engineering 08:30 - 09:00
AI for Antibody and TCR design - going beyond the static
  • Charlotte Deane, PhD - Professor of Structural Bioinformatics, University of Oxford
Antibody Engineering 09:00 - 09:30
What Do We Know About (y)our Antibodies? Novel Insights by New Approaches in Mass Spectrometry
  • Albert Heck, PhD - Professor of Chemistry and Pharmaceutical Sciences, Utrecht University
Antibody Engineering 09:30 - 10:00
Novel Antibody Approaches in Future Drug Discovery
  • Jane Grogan, PhD - Executive Vice President & Head of Research, Biogen
Antibody Engineering 10:00 - 10:30
Trim-Away: Using Cytosolic Antibodies for Targeted Protein Degradation
Antibody Engineering 10:30 - 11:00
Leveraging Human Genetics for Discovery of ATV-enabled Therapeutics for Alzheimer's Disease
  • Kathryn (Kate) Monroe, PhD - Director and Principal Scientist, Denali Therapeutics
Antibody Engineering 11:00 - 11:30
Probing the Role of 4R-tau in 10+16 MAPT Mutant iPSC-derived Neurones via Isoform-specific Antibody-mediated Degradation
  • Dale Starkie, PhD - Director, DJS Antibodies
Antibody Engineering 11:30 - 12:00
Characterising Vaccine-induced Human Monoclonal Antibodies to PfRH5 - The Leading Blood-stage Malaria Vaccine Target
  • Kristy McHugh, PhD - Senior Postdoctoral Scientist, University of Oxford
Antibody Engineering 12:00 - 12:30
Engineering Multispecifics from Human Antibodies for the Treatment of Allergies
  • Yvi Stark - Senior Scientist, Mabylon AG
Antibody Engineering 12:30 - 13:00
Nanobodies from Transgenic ‘LamaMice’
  • Friedrich Koch-Nolte, PhD - Professor of Immunology and Molecular Biology, University Medical Center Hamburg-Eppend
Antibody Engineering 13:00 - 13:30
Advancing Antibody Discovery and Functional Screening with Nanovials and Flow Cytometry
  • Joe de Rutte, PhD - Co-Founder and President, Partillion Bioscience
Choose Day